汇丰研究发表报告指，恒瑞医药(01276.HK) 2026上半年业绩因政策不确定性及国内激烈竞争而低于市场预期。惟全面的全球管线III期进展有望支持股价重估。维持“买入”评级，目标价由88.5元降至73.7元。该行将恒瑞医药2026至2028年收入预测下调6%至10%，因国内激烈竞争及政策不确定性而削减产品销售预测。基于有效成本控制，将其2026至2028年销售费用下调2%至4%，同时因海外...
Source Link汇丰研究发表报告指，恒瑞医药(01276.HK) 2026上半年业绩因政策不确定性及国内激烈竞争而低于市场预期。惟全面的全球管线III期进展有望支持股价重估。维持“买入”评级，目标价由88.5元降至73.7元。该行将恒瑞医药2026至2028年收入预测下调6%至10%，因国内激烈竞争及政策不确定性而削减产品销售预测。基于有效成本控制，将其2026至2028年销售费用下调2%至4%，同时因海外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.